This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waters, D. Articles by Lespérance, J. Search for Related Content PubMed PubMed Citation Articles by Waters, D. Articles by Lespérance, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CHOLESTEROL LOVASTATIN Medline Plus Health Information Coronary Artery Disease

(Circulation. 1995;92:2404-2410.)
© 1995 American Heart Association, Inc.

Articles

Effects of Cholesterol Lowering on the Progression of Coronary Atherosclerosis in Women

A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy

Presented in part at the American College of Cardiology 43rd Annual Scientific Session, Atlanta, Georgia, March 13-17, 1994, and published in abstract form (J Am Coll Cardiol. 1994;23:455A).

David Waters, MD; Lyall Higginson, MD; Peter Gladstone, MD; Stephen J. Boccuzzi, PhD; Thomas Cook, MS; Jacques Lespérance, MD for the CCAIT Study Group

Correspondence to David Waters, MD, Division of Cardiology, Hartford Hospital, 80 Seymour St, Hartford, CT 06102-5037.

Background Although coronary disease is the leading cause of death in women and its clinical features differ from those in men, very few women have been included in angiographic trials of cholesterol lowering.

Methods and Results Sixty-two women with diffuse but not necessarily severe coronary atherosclerosis documented on a recent angiogram and with fasting serum cholesterol between 220 and 300 mg/dL were enrolled in a double-blind, placebo-controlled trial. More than one half had a history of hypertension, approximately one quarter were diabetics, and one third were current smokers. All women received dietary counseling. Lovastatin or placebo was begun at 20 mg/d and was titrated if necessary to 40 and then to 80 mg during the first 16 weeks to attain a fasting LDL cholesterol 130 mg/dL. The mean lovastatin dose was 34 mg/d. Total and LDL cholesterol decreased by 24% and 32%, respectively, in lovastatin-treated women but by <3% in women receiving placebo. Coronary arteriography was repeated after 2 years in 54 women (87%), and their 394 lesions were measured "blindly" on pairs of film with an automated computerized quantitative system. Progression, defined as a worsening in minimum diameter of one or more stenoses by 0.4 mm, occurred in 7 of 25 lovastatin-treated women and 17 of 29 placebo-treated women (28% versus 59%, P=.031). New coronary lesions developed in 1 lovastatin-treated woman and 13 placebo-treated women (4% versus 45%, P<.001). The outcome for each of the angiographic end points was not significantly different between the women and the 245 men who completed the trial.

Conclusions Lovastatin slows the progression of coronary atherosclerosis and prevents the development of new coronary lesions in women.

Key Words: atherosclerosis • women • coronary disease • cholesterol

This article has been cited by other articles:

				H. R. Superko and S. King III Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required Circulation, January 29, 2008; 117(4): 560 - 568. [Full Text] [PDF]

				P. Amarenco, J. Labreuche, P. Lavallee, and P.-J. Touboul Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis Stroke, December 1, 2004; 35(12): 2902 - 2909. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]

				R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]

				P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology, September 1, 2001; 57(90002): S35 - 44. [Abstract] [Full Text]

				F. K. Welty Cardiovascular Disease and Dyslipidemia in Women Arch Intern Med, February 26, 2001; 161(4): 514 - 522. [Abstract] [Full Text] [PDF]

				A. M. Malek, S. L. Alper, and S. Izumo Hemodynamic Shear Stress and Its Role in Atherosclerosis JAMA, December 1, 1999; 282(21): 2035 - 2042. [Abstract] [Full Text] [PDF]

				J M. Gaziano, C. H Hennekens, S. Satterfield, C. Roy, H. D Sesso, J. L Breslow, and J. E Buring Clinical utility of lipid and lipoprotein levels during hospitalization for acute myocardial infarction Vascular Medicine, November 1, 1999; 4(4): 227 - 231. [Abstract] [PDF]

				S. D. Ross, I. E. Allen, J. E. Connelly, B. M. Korenblat, M. E. Smith, D. Bishop, and D. Luo Clinical Outcomes in Statin Treatment Trials: A Meta-analysis Arch Intern Med, August 9, 1999; 159(15): 1793 - 1802. [Abstract] [Full Text] [PDF]

				R. P. Byington, G. W. Evans, M. A. Espeland, W. B. Applegate, D. B. Hunninghake, J. Probstfield, and C. D. Furberg Effects of Lovastatin and Warfarin on Early Carotid Atherosclerosis : Sex-Specific Analyses Circulation, July 20, 1999; 100 (3): e14 - e17. [Abstract] [Full Text] [PDF]

				M. R. Wise, D. E. Stewart, P. Liu, and B. L. Abramson Use of hormone replacement therapy among cardiac patients at a Canadian academic centre Can. Med. Assoc. J., July 1, 1999; 161(1): 33 - 36. [Abstract] [Full Text] [PDF]

				V. Guetta and R. O. Cannon III Cardiovascular Effects of Estrogen and Lipid-Lowering Therapies in Postmenopausal Women Circulation, May 15, 1996; 93(10): 1928 - 1937. [Full Text]

				CHOLESTEROL LOWERING BENEFITS WOMEN, TOO Journal Watch (General), November 17, 1995; 1995(1117): 2 - 2. [Full Text]